Browse SUSD2

Summary
SymbolSUSD2
Namesushi domain containing 2
Aliases BK65A6.2; FLJ22778; Sushi domain (SCR repeat) containing; Sushi domain-containing protein 2
Chromosomal Location22q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Note=SUSD2 and LGALS1 co-localized in very specific, punctate regions along the cell membrane of breast cancer cells.
Domain PF03782 AMOP domain
PF01033 Somatomedin B domain
PF00084 Sushi repeat (SCR repeat)
PF00094 von Willebrand factor type D domain
Function

May be a cytokine receptor for C10ORF99. May be a tumor suppressor; together with C10ORF99 has a growth inhibitory effect on colon cancer cells which includes G1 cell cycle arrest (PubMed:25351403). May play a role in breast tumorigenesis (PubMed:23131994).

> Gene Ontology
 
Biological Process GO:0006898 receptor-mediated endocytosis
GO:0010948 negative regulation of cell cycle process
GO:0044770 cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045786 negative regulation of cell cycle
GO:0051302 regulation of cell division
GO:0051782 negative regulation of cell division
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
Molecular Function GO:0001871 pattern binding
GO:0005044 scavenger receptor activity
GO:0030246 carbohydrate binding
GO:0030247 polysaccharide binding
GO:0038024 cargo receptor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSUSD2
Namesushi domain containing 2
Aliases BK65A6.2; FLJ22778; Sushi domain (SCR repeat) containing; Sushi domain-containing protein 2
Chromosomal Location22q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SUSD2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SUSD2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23131994Breast carcinomaInhibit immunity; immunotherapy targetVarious phenotype assays indicate that SUSD2 increases the invasion of breast cancer cells and contributes to a potential immune evasion mechanism through induction of apoptosis of Jurkat T cells. Using a syngeneic mouse model, we observed accelerated tumor formation and decreased survival in mice with tumors expressing Susd2. We found significantly fewer CD4 tumor infiltrating lymphocytes in mice with tumors expressing Susd2. Together, our findings provide evidence that SUSD2 may represent a promising therapeutic target for breast cancer.
Summary
SymbolSUSD2
Namesushi domain containing 2
Aliases BK65A6.2; FLJ22778; Sushi domain (SCR repeat) containing; Sushi domain-containing protein 2
Chromosomal Location22q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SUSD2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSUSD2
Namesushi domain containing 2
Aliases BK65A6.2; FLJ22778; Sushi domain (SCR repeat) containing; Sushi domain-containing protein 2
Chromosomal Location22q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SUSD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9360.0613
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.6340.165
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4220.642
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.160.742
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4060.811
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1410.94
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1110.82
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6160.495
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.9210.345
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6670.514
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6760.632
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0780.667
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SUSD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.78.2-4.50.671
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.710.2-6.50.425
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSUSD2
Namesushi domain containing 2
Aliases BK65A6.2; FLJ22778; Sushi domain (SCR repeat) containing; Sushi domain-containing protein 2
Chromosomal Location22q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SUSD2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSUSD2
Namesushi domain containing 2
Aliases BK65A6.2; FLJ22778; Sushi domain (SCR repeat) containing; Sushi domain-containing protein 2
Chromosomal Location22q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SUSD2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SUSD2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSUSD2
Namesushi domain containing 2
Aliases BK65A6.2; FLJ22778; Sushi domain (SCR repeat) containing; Sushi domain-containing protein 2
Chromosomal Location22q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SUSD2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSUSD2
Namesushi domain containing 2
Aliases BK65A6.2; FLJ22778; Sushi domain (SCR repeat) containing; Sushi domain-containing protein 2
Chromosomal Location22q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SUSD2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSUSD2
Namesushi domain containing 2
Aliases BK65A6.2; FLJ22778; Sushi domain (SCR repeat) containing; Sushi domain-containing protein 2
Chromosomal Location22q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SUSD2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSUSD2
Namesushi domain containing 2
Aliases BK65A6.2; FLJ22778; Sushi domain (SCR repeat) containing; Sushi domain-containing protein 2
Chromosomal Location22q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SUSD2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.